RFK Jr.’s vaccine panel weakens Covid shot recommendations, calling it an individual decision

RFK Jr.’s vaccine panel weakens Covid shot recommendations, calling it an individual decision


Members of the Advisory Committee on Immunization Practices (ACIP) listen to a presentation about COVID-19 (coronavirus disease) during an Advisory Committee on Immunization Practices (ACIP) meeting at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S., Sept. 19, 2025.

Alyssa Pointer | Reuters

Health and Human Services Secretary Robert F. Kennedy Jr.’s hand-picked vaccine panel on Friday weakened Covid shot recommendations in the U.S., advising that all Americans receive one based on consultations with a health-care provider. 

The panel, called the Advisory Committee on Immunization Practices, or ACIP, recommended that people 6 months and up receive vaccines based on so-called “shared clinical decision-making,” which refers to a decision process between a health-care provider and a patient or their guardian. The group also voted to emphasize that the Covid vaccine is beneficial for those at high risk of severe illness from the disease.

The guidance breaks from previous years, where the committee recommended that all Americans ages 6 months and up receive an updated Covid shot. 

The vote is no surprise, as Kennedy appointed several vocal critics of mRNA Covid shots to the panel after ousting all previous members in June. ACIP sets recommendations on who should receive certain shots and which vaccines insurers must cover at no cost. 

Massachusetts Institute of Technology Professor Retsef Levi speaks during an Advisory Committee on Immunization Practices (ACIP) meeting at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S., Sept. 19, 2025.

Alyssa Pointer | Reuters

It also comes after Kennedy’s other recent moves to change U.S. Covid vaccine policy, which has left many Americans confused and created new hurdles for some people accessing vaccines. The Centers for Disease Control and Prevention dropped Covid shot recommendations for healthy kids and pregnant women, and the Food and Drug Administration approved new Covid jabs with limits on who can get them. 

The CDC, whose latest director was ousted by the Trump administration earlier this month, still has to adopt the panel’s recommendations. 

Public health experts previously told CNBC that weakening recommendations for Covid vaccines could make it harder for some people — especially healthy adults and children, along with those in rural areas — to access the shots and have them covered by insurance. The ability to get vaccines will likely vary by state: In a break from federal guidelines, four Democratic states on Wednesday recommended that broad swaths of the population receive an updated Covid shot, including “all who choose protection.”

Still, any new limits on access could further weaken vaccination rates against the virus and heighten the threat of the disease spreading. 

A study published Thursday in JAMA Network Open showed that sticking to a universal Covid vaccine recommendation in the U.S., the guidance that has been in place in recent years, has the potential to prevent thousands more hospitalizations and deaths than limiting the advisory to high-risk groups. 

Numerous studies have demonstrated that shots using mRNA technology, including Covid vaccines from Pfizer and Moderna, are safe and effective, and serious side effects have happened in extremely rare cases. One paper in August estimates that Covid vaccines saved more than 2 million lives, mostly among older adults, worldwide between 2020 and October 2024. 

One major health insurance group on Wednesday said its member plans will cover all vaccines already recommended by ACIP, including updated Covid and flu shots, despite any changes the new slate of appointees makes this week. Member plans of the group, America’s Health Insurance Plans, collectively provide coverage and services to over 200 million Americans. That includes more than a dozen Blue Cross Blue Shield plans, Centene, CVS’s Aetna, Elevance Health, Humana, Kaiser Permanente, Molina, and Cigna.

Debating Covid vaccines

One member, Retsef Levi, led a work group that reviewed data and proposed recommendations around Covid vaccines. Levi’s presentation on the group’s findings questioned the safety and efficacy of Covid shots and cast doubt on mRNA technology.

“We have a range of things on the mRNA platforms that really suggest that it doesn’t work as intended,” said Levi, who has previously pushed to stop giving mRNA shots.

He said the majority of the work group felt that individual-based decisions on whether to receive a Covid vaccine are “appropriate” and specifically, that people should now have to obtain prescriptions for the shot. Levi said, “you get to a level of nuance” where some patients may have recent prior infections or different comorbidities that should be discussed with a physician as part of a prescription. 

But one work group member, Dr. Henry Bernstein, said during an additional presentation that “shared clinical decision-making and a need for a prescription creates barriers” to Covid vaccine access. 

“Simple, stable recommendations can increase vaccine coverage. Covid-19 vaccines are highly safe and effective,” Bernstein, a professor of pediatrics at Zucker School of Medicine at Hofstra/Northwell. He is not a member of Kennedy’s panel who votes on recommendations.

“Covid-19 vaccination matters for pregnant women, pediatric patients, especially those less than two years of age, people 65 years and older, those of any age with a weakened immune system, medical conditions, and anyone who feels they want protection for themselves or their families,” he said. 



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More